A PHASE II STUDY OF ERLOTINIB AND CHEMOTHERAPY FOR PATIENTS WITH STAGE IB-IIIA NSCLC WITH EGFR MUTATIONS (ECON).

Trial Profile

A PHASE II STUDY OF ERLOTINIB AND CHEMOTHERAPY FOR PATIENTS WITH STAGE IB-IIIA NSCLC WITH EGFR MUTATIONS (ECON).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ECON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top